Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 5/20 | 0.36 |
| ▸ | KDR | P35968 | 5/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 6/20 | 0.34 |
| ▸ | FAAH | O00519 | 2/20 | 0.34 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | CCR3 | P51677 | 1/20 | 0.31 |
| ▸ | CCKAR | P32238 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4890256 | 0.79 | NAMPT (0.40) | ALDH1A1 | |
| SCHEMBL4879679 | 0.79 | NR1H2 (0.36) | ALDH1A1RAB9A | |
| SCHEMBL4884428 | 0.78 | IGF1R (0.33) | — | |
| SCHEMBL4884670 | 0.77 | IGF1R (0.34) | ALDH1A1 | |
| SCHEMBL4885935 | 0.77 | IGF1R (0.39) | ALDH1A1 | |
| SCHEMBL4882154 | 0.76 | IGF1R (0.32) | — | |
| SCHEMBL2940400 | 0.75 | IGF1R (0.35) | — | |
| SCHEMBL3730438 | 0.74 | MAPT (0.34) | ALDH1A1RAB9A | |
| SCHEMBL5480183 | 0.74 | AR (0.46) | ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL5177062 | 0.72 | IGF1R (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259891-A1 | Heterocycle-Substituted Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2007-11-08 | — | — | US | disclosed |
| EP-1621539-A1 | Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | Aventis Pharma S.A. (FR) | 2006-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259891-A1 | Heterocycle-Substituted Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors | CDK1, PRKAR2B, MAP3K19 | FLT1 958/4885KDR 1109/4885EGLN1 2335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.